There have been 11 cancer-related novel drug approvals in 2024, according to the FDA website.
Novel drugs are new drugs that, prior to approval, have never been marketed in the U.S.
|
Drug Name |
Active Ingredient |
Approval Date |
FDA-approved Use |
|
Ziihera |
zanidatamab-hrii |
11/20/2024 |
To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer |
|
Revuforj |
revumenib |
11/15/2024 |
To treat relapsed or refractory acute leukemia |
|
Vyloy |
zolbetuximab-clzb |
10/18/2024 |
To treat gastric or gastroesophageal junction adenocarcinoma |
|
Itovebi |
inavolisib |
10/10/2024 |
To treat locally advanced or metastatic breast cancer |
|
Lazcluze |
lazertinib |
8/19/2024 |
To treat non-small cell lung cancer |
|
Voranigo |
vorasidenib |
8/6/2024 |
To treat Grade 2 astrocytoma or oligodendroglioma |
|
Imdelltra |
tarlatamab-dlle |
5/16/2024 |
To treat extensive stage small cell lung cancer |
|
Ojemda |
tovorafenib |
4/23/2024 |
To treat relapsed or refractory pediatric low-grade glioma |
|
Anktiva |
nogapendekin alfa inbakicept-pmln |
4/22/2024 |
To treat bladder cancer |
|
Lumisight |
pegulicianine |
4/17/2024 |
To use as an optical imaging agent for the detection of cancerous tissue |
|
Tevimbra |
tislelizumab-jsgr |
3/13/2024 |
To treat unresectable or metastatic esophageal squamous cell carcinoma |